MK319 is an AKR1B10 inhibitor. AKR1B10 has evolved as a tumor marker and promising antineoplastic target. It shares high structural similarity with the diabetes target enzyme aldose reductase (AR).
Uses
MK 319 is a selective aldose reductase (AR) inhibitor with an IC50 of 0.3 μM. MK 319 can be utilized in diabetes research[1].
References
[1] Cousido-Siah A, et al. IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors. ACS Chem Biol. 2016 Oct 21;11(10):2693-2705. DOI:10.1021/acschembio.6b00382
